Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I. Khan K, et al. Among authors: thomas j. Oncotarget. 2016 Mar 15;7(11):12672-81. doi: 10.18632/oncotarget.7208. Oncotarget. 2016. PMID: 26862857 Free PMC article. Clinical Trial.
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I. Starling N, et al. Among authors: thomas j. Br J Cancer. 2009 Jun 2;100(11):1725-30. doi: 10.1038/sj.bjc.6605070. Epub 2009 May 12. Br J Cancer. 2009. PMID: 19436301 Free PMC article. Clinical Trial.
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I. Wong R, et al. Among authors: thomas j. Ann Oncol. 2011 Sep;22(9):2042-2048. doi: 10.1093/annonc/mdq714. Epub 2011 Feb 1. Ann Oncol. 2011. PMID: 21285134 Free article. Clinical Trial.
A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Starling N, Hawkes EA, Chau I, Watkins D, Thomas J, Webb J, Brown G, Thomas K, Barbachano Y, Oates J, Cunningham D. Starling N, et al. Among authors: thomas j, thomas k. Ann Oncol. 2012 Apr;23(4):942-7. doi: 10.1093/annonc/mdr317. Epub 2011 Jul 12. Ann Oncol. 2012. PMID: 21750117 Free article. Clinical Trial.
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ, Starling N, Cunningham D, Thomas J, Webb J, Brown G, Barbachano Y, Oates J, Chau I. Watkins DJ, et al. Among authors: thomas j. Eur J Cancer. 2014 May;50(8):1422-9. doi: 10.1016/j.ejca.2014.02.003. Epub 2014 Mar 6. Eur J Cancer. 2014. PMID: 24613126 Clinical Trial.
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.
Khan K, Rata M, Cunningham D, Koh DM, Tunariu N, Hahne JC, Vlachogiannis G, Hedayat S, Marchetti S, Lampis A, Damavandi MD, Lote H, Rana I, Williams A, Eccles SA, Fontana E, Collins D, Eltahir Z, Rao S, Watkins D, Starling N, Thomas J, Kalaitzaki E, Fotiadis N, Begum R, Bali M, Rugge M, Temple E, Fassan M, Chau I, Braconi C, Valeri N. Khan K, et al. Among authors: thomas j. Gut. 2018 Aug;67(8):1484-1492. doi: 10.1136/gutjnl-2017-314178. Epub 2017 Aug 8. Gut. 2018. PMID: 28790159 Free PMC article. Clinical Trial.
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.
Sclafani F, Gonzalez de Castro D, Cunningham D, Hulkki Wilson S, Peckitt C, Capdevila J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Begum R, Thomas J, Oates J, Chau I. Sclafani F, et al. Among authors: thomas j. Clin Cancer Res. 2014 Sep 1;20(17):4511-9. doi: 10.1158/1078-0432.CCR-14-0674. Epub 2014 Jul 1. Clin Cancer Res. 2014. PMID: 24987061 Clinical Trial.
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial.
Anandappa G, Lampis A, Cunningham D, Khan KH, Kouvelakis K, Vlachogiannis G, Hedayat S, Tunariu N, Rao S, Watkins D, Starling N, Braconi C, Darvish-Damavandi M, Lote H, Thomas J, Peckitt C, Kalaitzaki R, Khan N, Fotiadis N, Rugge M, Begum R, Rana I, Bryant A, Hahne JC, Chau I, Fassan M, Valeri N. Anandappa G, et al. Among authors: thomas j. Clin Cancer Res. 2019 Jul 1;25(13):3830-3838. doi: 10.1158/1078-0432.CCR-18-3769. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952636 Free article. Clinical Trial.
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, Evans J, Yu S, Sena Teixeira Mendes L, Tabernero J, Glimelius B, Cervantes A, Thomas J, Begum R, Oates J, Chau I. Sclafani F, et al. Among authors: thomas j. Ann Oncol. 2016 Aug;27(8):1557-65. doi: 10.1093/annonc/mdw215. Epub 2016 May 23. Ann Oncol. 2016. PMID: 27217542 Free article. Clinical Trial.
14,255 results
You have reached the last available page of results. Please see the User Guide for more information.